NFKB1 and idiopathic pulmonary fibrosis: We demonstrated that PKCδ inhibits the activation of the NF-κB signal pathway by binding and phosphorylating A20, which in turn reduces the expression of IL-33 and alleviates IPF, suggesting that PKCδ is a potential drug target for treating IPF.